TIDMOBD
RNS Number : 8089J
Oxford BioDynamics PLC
18 August 2023
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE
RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION,
DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED
STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF
SOUTH AFRICA OR JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE TO
DO SO WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
UNLESS OTHERWISE INDICATED, CAPITALISED TERMS IN THIS
ANNOUNCEMENT HAVE THE MEANINGS GIVEN TO THEM IN THE DEFINITIONS
SECTION OF THE CIRCULAR TO SHAREHOLDERS OF THE COMPANY ON 2 AUGUST
2023.
Oxford BioDynamics PLC
("OBD", the "Company" or together with its subsidiaries, the
"Group")
Result of General Meeting
Director/PDMR Dealings
Oxford, UK 18 August 2023 Oxford BioDynamics PLC (AIM: OBD,
"OBD" or the "Company"), a biotechnology company developing
precision medicine tests based on the EpiSwitch(R) 3D genomics
platform, announces that all resolutions proposed at the general
meeting of the Company held earlier today were duly passed.
Further to the passing of the resolutions at the general meeting
of the Company held earlier today, application has been made for
22,457,268 new Ordinary Shares (comprising the VCT/EIS Shares to be
issued pursuant to the Placing) to be admitted to trading on the
AIM market ("AIM") of the London Stock Exchange ("VCT/EIS
Admission"). Application has also been made for 33,133,767 new
Ordinary Shares (comprising the General Placing Shares,
Subscription Shares and PrimaryBid Shares to be issued pursuant to
the Placing, Subscription and PrimaryBid Offer) to be admitted to
trading on AIM ("General Admission").
It is expected that VCT/EIS Admission will take place, and
trading in the VCT/EIS Shares will commence, at 8.00 a.m. on 21
August 2023 and that General Admission will take place, and trading
in the General Placing Shares, Subscription Shares and PrimaryBid
Shares will commence at 8.00 a.m. on 22 August 2023.
Following VCT/EIS Admission, the Company's issued ordinary share
capital and total voting rights will consist of 169,169,648
Ordinary Shares. Following General Admission, the Company's issued
ordinary share capital and total voting rights will consist of
202,303,415 Ordinary Shares. These figures should be used by
shareholders as the denominator for the calculation by which they
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure
Guidance and Transparency Rules.
In addition to the Related Party Transactions disclosed in
Section 7 of Part I of the Circular to Shareholders dated 2 August
2023 and the Company's announcement of 2 August 2023, Dr Alexandre
Akoulitchev, Chief Scientific Officer, subscribed for 300,000
shares in the PrimaryBid Offer. In line with the intention outlined
in the Circular, Paul Stockdale, Chief Financial Officer,
subscribed for 90,909 Ordinary Shares in the PrimaryBid Offer. The
independent directors of the Company (being all of the Directors
other than Alexandre Akoulitchev and Paul Stockdale) having
consulted with the Company's nominated adviser, Shore Capital,
consider the terms of Alexandre Akoulitchev and Paul Stockdale's
aggregate subscription for New Ordinary Shares to be fair and
reasonable insofar as the Company's Shareholders are concerned.
The total New Ordinary Shares subscribed for pursuant to the
Placing, Subscription and PrimaryBid Offer by the Directors and
PDMRs who are participating in the Fundraising, are set out
below:
Director/PDMR Existing Fundraising Beneficial Shareholding
beneficial Shares shareholding as a percentage
shareholding following of the Enlarged
the Fundraising Issued Share
Capital
Dr Alexandre Akoulitchev 6,303,082 300,000 6,603,082 3.26%
-------------- ------------ ----------------- -----------------
Dr Jon Burrows 300,000 400,000 700,000 0.35%
-------------- ------------ ----------------- -----------------
Stephan Diggle* 19,257,847 9,090,909 28,348,756 14.01%
-------------- ------------ ----------------- -----------------
Thomas Guiel 175,000 190,000 365,000 0.18%
-------------- ------------ ----------------- -----------------
Dr Ewan Hunter - 136,363 136,363 0.07%
-------------- ------------ ----------------- -----------------
Paul Stockdale 150,000 181,818 331,818 0.16%
-------------- ------------ ----------------- -----------------
Matthew Wakefield 750,000 272,727 1,022,727 0.51%
-------------- ------------ ----------------- -----------------
* Stephen Diggle's beneficial shareholding is held through the
Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are
controlled by him.
Director/PDMR Dealings
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Matthew Wakefield
-------------------------- -------------------------------------
Reason for the notification
2
-----------------------------------------------------------------
a) Position/status Chairman
-------------------------- -------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 272,727
----------
-------------------------- -------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- -------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
-----------------------------------------------------------------
a) Name Dr Jon Burrows
-------------------------- -------------------------------------
Reason for the notification
2
-----------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- -------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
Details of the transaction(s): section to be repeated for
4 (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 400,000
----------
-------------------------- -------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- -------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Alexandre Akoulitchev
-------------------------- -------------------------------------
2 Reason for the notification
-----------------------------------------------------------------
a) Position/status Chief Scientific Officer
-------------------------- -------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 300,000
----------
-------------------------- -------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- -------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Paul Stockdale
-------------------------- -------------------------------------
2 Reason for the notification
-----------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- -------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 181,818
----------
-------------------------- -------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- -------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Vulpes Investment Management (a PCA
of Stephen Diggle) through Vulpes
Life Sciences Fund
-------------------------- ---------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Person closely associated with Non-Executive
Director
-------------------------- ---------------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- ---------------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- ---------------------------------------------
b) Nature of the transaction Purchase
-------------------------- ---------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 9,090,909
----------
-------------------------- ---------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ---------------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- ---------------------------------------------
f) Place of the transaction Off market
-------------------------- ---------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Thomas Guiel
-------------------------- -------------------------------------
2 Reason for the notification
-----------------------------------------------------------------
a) Position/status Chief Operating Officer
-------------------------- -------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 190,000
----------
-------------------------- -------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- -------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Ewan Hunter
-------------------------- -------------------------------------
2 Reason for the notification
-----------------------------------------------------------------
a) Position/status Chief Data Officer
-------------------------- -------------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------
a) Name Oxford BioDynamics Plc
-------------------------- -------------------------------------
b) LEI 2138005Y1TK258O5U928
-------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------
a) Description of the Ordinary Shares of 1p par value each
financial instrument,
type of instrument ISIN: GB00BD5H8572
Identification code
-------------------------- -------------------------------------
b) Nature of the transaction Purchase
-------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
GBP0.11 136,363
----------
-------------------------- -------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------
e) Date of the transaction 18 August 2023
-------------------------- -------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------
For more information:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
PrimaryBid Limited enquiries@primarybid.com
Fahim Chowdhury/James Deal
Shore Capital - Nominated Adviser Tel: +44 (0)20 7408
Stephane Auton / Iain Sexton 4090
Instinctif Partners - Financial PR Tel: +44 (0)20 7457
Melanie Toyne-Sewell / Rozi Morris / Adam 2020
Loudon OxfordBioDynamics@instinctif.com
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor
Response Test) for cancer, a predictive immune response profile for
immuno-oncology (IO) checkpoint inhibitor treatments, launched in
February 2022.
OBD's next commercial product will be the Prostate Screening
EpiSwitch(R) (PSE) blood test, due to be launched in Q4 2023.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch(R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit , which is available for purchase by the life science
research community.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for the prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial office in
Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a
reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow OBD on Twitter
(@OxBioDynamics) and LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcomes, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMSFDFSAEDSELA
(END) Dow Jones Newswires
August 18, 2023 06:44 ET (10:44 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024
